These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 1789901)
21. Enterobacter cloacae outer membrane permeability to ceftizoxime (FK 749) and five other new cephalosporin derivatives. Kojo H; Shigi Y; Nishida M J Antibiot (Tokyo); 1980 Mar; 33(3):317-21. PubMed ID: 6247313 [TBL] [Abstract][Full Text] [Related]
22. In vitro activity of cefpodoxime compared with other oral cephalosporins tested against 5556 recent clinical isolates from five medical centers. Sader HS; Jones RN; Washington JA; Murray PR; Gerlach EH; Allen SD; Erwin ME Diagn Microbiol Infect Dis; 1993; 17(2):143-50. PubMed ID: 8243035 [TBL] [Abstract][Full Text] [Related]
23. [Comparative antibacterial activity of cefpodoxime, cefuroxime and cefaclor against strict anaerobic bacteria]. Dubreuil L; Derriennic M; Sedallian A Pathol Biol (Paris); 1990 May; 38(5):343-6. PubMed ID: 2367150 [TBL] [Abstract][Full Text] [Related]
24. A multicentre study of the in-vitro activity of cefotaxime, cefuroxime, ceftazidime, ofloxacin and ciprofloxacin against blood and urinary pathogens. Amyes SG; Baird DR; Crook DW; Gillespie SH; Howard AJ; Oppenhiem BA; Pedler SJ; Paull A; Tompkins DS; Lawrie SA J Antimicrob Chemother; 1994 Nov; 34(5):639-48. PubMed ID: 7706159 [TBL] [Abstract][Full Text] [Related]
25. [Bacteriological in vitro studies with a new cephalosporin: cefotiam (author's transl)]. Grimm H Arzneimittelforschung; 1981; 31(11):1867-9. PubMed ID: 6274364 [TBL] [Abstract][Full Text] [Related]
27. [Sensitivity to second-generation cephem agents of clinically isolated strains of bacteria in otorhinolaryngological field (author's transl)]. Deguchi K; Kawamura S; Sugita R; Fujimaki Y; Ohsawa H Jpn J Antibiot; 1982 Mar; 35(3):812-20. PubMed ID: 6285017 [TBL] [Abstract][Full Text] [Related]
28. In vitro activity of ceftizoxime, ceftazidime, cefuroxime, ceftriaxone, cefotaxime, and penicillin against Streptococcus pneumoniae as determined by three quantitative methods. Barry AL; Brown SD; Fuchs PC Eur J Clin Microbiol Infect Dis; 1996 Apr; 15(4):344-6. PubMed ID: 8781889 [TBL] [Abstract][Full Text] [Related]
29. In vitro activity of ceftibuten against Haemophilus influenzae and Branhamella catarhallis. Doern GV Diagn Microbiol Infect Dis; 1991; 14(1):75-7. PubMed ID: 1901536 [TBL] [Abstract][Full Text] [Related]
30. [Minimal inhibitory and bactericidal concentrations of cefoperazone, cefotaxime, cefuroxime and cefalotin against 90 bacterial strains]. Mascellino MT; Prignano G; Iegri F; Lorenzi A Boll Ist Sieroter Milan; 1982; 61(4):309-19. PubMed ID: 6100234 [TBL] [Abstract][Full Text] [Related]
31. Presence of Clostridium difficile and antibiotic and beta-lactamase activities in feces of volunteers treated with oral cefixime, oral cefpodoxime proxetil, or placebo. Chachaty E; Depitre C; Mario N; Bourneix C; Saulnier P; Corthier G; Andremont A Antimicrob Agents Chemother; 1992 Sep; 36(9):2009-13. PubMed ID: 1416894 [TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic-pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models. Liu P; Rand KH; Obermann B; Derendorf H Int J Antimicrob Agents; 2005 Feb; 25(2):120-9. PubMed ID: 15664481 [TBL] [Abstract][Full Text] [Related]
33. In-vitro activities of trospectomycin, cefpodoxime, and second-generation cephalosporins against Haemophilus influenzae type b. LiPuma JJ; Daley B; Stull TL J Antimicrob Chemother; 1990 Apr; 25(4):535-9. PubMed ID: 2141018 [TBL] [Abstract][Full Text] [Related]
34. Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric patients. Fulton B; Perry CM Paediatr Drugs; 2001; 3(2):137-58. PubMed ID: 11269640 [TBL] [Abstract][Full Text] [Related]
35. [Comparative antibacterial activity of cefpodoxime against Haemophilus influenzae, Streptococcus pyogenes, Streptococcus pneumoniae and Moraxella catarrhalis]. Wallrauch-Schwarz C; Milatovic D; Braveny I Arzneimittelforschung; 1994 May; 44(5):668-70. PubMed ID: 8024645 [TBL] [Abstract][Full Text] [Related]
36. In vitro activity of cefpodoxime proxetil (U-76,252; CS-807) against Neisseria gonorrhoeae. Schaadt RD; Yagi BH; Zurenko GE Antimicrob Agents Chemother; 1990 Feb; 34(2):371-2. PubMed ID: 2109583 [TBL] [Abstract][Full Text] [Related]
37. Comparable evaluation of orally active beta-lactam compounds in ampicillin-resistant gram-positive and gram-negative rods: role of beta-lactamases on resistance. Cullmann W; Dick W; Stieglitz M; Opferkuch W Chemotherapy; 1988; 34(3):202-15. PubMed ID: 3262045 [TBL] [Abstract][Full Text] [Related]
38. Antibacterial activity of cefpodoxime proxetil in a pharmacokinetic in-vitro model. Wiedemann B; Jansen A J Antimicrob Chemother; 1990 Jul; 26(1):71-9. PubMed ID: 2211449 [TBL] [Abstract][Full Text] [Related]
39. [In vitro comparative effect of cefixime and 7 other beta-lactamines against Streptococcus pneumoniae]. Boussougant Y; Weber P Presse Med; 1989 Oct; 18(32):1553-5. PubMed ID: 2530530 [TBL] [Abstract][Full Text] [Related]
40. In vitro activity of cefixime: correlation index between MIC and disc diffusion test. FocĂ A; Liberto MC; Berlinghieri MC; Matera G; Puccio R; Carbone M; Fera MT Drugs Exp Clin Res; 1990; 16(4):175-9. PubMed ID: 2076653 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]